isvav_result

publication_year

occurrences__organization__code

solver__id__sc2

result_type__code

Type of result according to the RIV classification. Czech version is available <a href="https://www.vyzkum.cz/FrontClanek.aspx?idsekce=1395" target="_blank" >here</a>.

language__code

Jazyk výsledku udáva původní jazyk, ve kterém byl daný výsledek vytvořen. Kompletní seznam jazyků ve kterém je možno výsledek do RIV předložit je <a href="https://www.vyzkum.cz/FrontClanek.aspx?idsekce=1397" target="_blank" >zde</a>.

cep__code

ford__code

_group_id67

occurrences__funder__code

Data supplier is the R&D aid provider who supported this result.

project__programme__code

x_range_count_solvers

project__id

What are you looking for?

Quick search

Smart search

Filters

Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

Efekt léčby pomalidomidem u silně předléčeného pacienta s klinicky velmi nepříznivým mnohočetným myelomem

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label